The rationale for early postoperative intraperitoneal chemotherapy for gastric cancer

  • W. J. Cunliffe
Part of the Cancer Treatment and Research book series (CTAR, volume 55)


Gastric cancer is still a major source of morbidity and mortality worldwide [1], despite the falling incidence in many countries [2–4]. The average patient presenting with a primary gastric malignancy in Europe or the United States undergoing surgery will face a mortality rate of 10% or more, with fewer than 20% surviving 5 years [5]. In a large European study of over 13,000 patients [6], the 5- and 10-year survival was 5.5% and 3.8%, respectively, with 73% of patients not undergoing resection. An update of this study demonstrated that over a 25-year period, the incidence fell from 17.4/100,000 to 15.3/ 100,000, with 79% of patients having stage IV disease and with only 1 % having stage I disease; curative resection was undertaken in only 21 %, and the resulting mortality rate for partial and total gastrectomy was 13% and 29%, respectively; the 5-year survival rate was 5% overall [7]. In Japan, in contrast to these dismal results, a reduction in the operative mortality rate and a corresponding increase in the 5-year survival rate has been achieved [8]. This may well be as a result of the cooperation between endoscopists, surgeons, and pathologists [9], which will be discussed later. Both adjuvant radiotherapy and chemotherapy have been used in order to prolong survival, although so for without success [1], and this topic is fully discussed elsewhere in the book.


Gastric Cancer Early Gastric Cancer Basal Cell Carcinoma Intestinal Metaplasia Peritoneal Surface 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cunliffe WJ, Sugarbaker PH, 1989. Gastrointestinal malignancy: Rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg 76:1082–1090.PubMedCrossRefGoogle Scholar
  2. 2.
    The Gastrointestinal Tumor Study Group, 1982. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 49:1116–1122.CrossRefGoogle Scholar
  3. 3.
    Moertel CG, Childs DS, O’Fallon JR et al., 1984. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 2:1249–1254.PubMedGoogle Scholar
  4. 4.
    Greig RG, Schein PS, 1986. Therapy of gastrointestinal cancer. Scand J Gastroenterol 117:9–25.Google Scholar
  5. 5.
    DuPont JB Jr., Lee JR, Burton GR, et al., 1978. Adenocarcinoma of the stomach: Review of 1497 cases. Cancer 41:941–947.CrossRefGoogle Scholar
  6. 6.
    Fielding JWL, Roginski C, Ellis DJ, et al., 1984. Clinicopathological staging of gastric cancer. Br J Surg 71:677–680.PubMedCrossRefGoogle Scholar
  7. 7.
    Allum WH, Powell DJ, McConkey CC, Fielding JWL, 1989. Gastric cancer: A 25 year review. Br J Surg 76:535–540.PubMedCrossRefGoogle Scholar
  8. 8.
    Craven JL, 1986. Radical surgery for gastric cancer. In Cancer of the Stomach (Preece PR, Cushieri A, Wellwood JM, eds). London: Grune and Stratton, pp. 165–187.Google Scholar
  9. 9.
    Japanese Research Society for Gastric Cancer, 1981. The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg 11:127–139.CrossRefGoogle Scholar
  10. 10.
    Borrmann R, 1926. Geschwulste des Magens und Duodenums. In Handbuch der Speziellen Pathologischen Anatomie und Histologie, Vol. 4 (Henke F, Lunbarsch O, eds). Berlin: Julius Springer, p. 812.Google Scholar
  11. 11.
    Lauren P, 1965. The two histologic main types of gastric carcinoma: Diffuse and so-called intestinal type carcinoma. Acta Pathol Microbiol Scand 64:31–49.PubMedGoogle Scholar
  12. 12.
    Mulligan RM, Rember RH, 1954. Histogenesis and biologic behaviour of gastric carcinoma. Arch Pathol 58:1–25.Google Scholar
  13. 13.
    Ewing J, 1919. In Neoplastic Diseases. Philadelphia: W.B. Saunders, pp. 605–639.Google Scholar
  14. 14.
    Kotanagi H, Yamaguchi K, Khono K, Takahashi T, 1980. Comparative study of early gastric cancer in the young and the aged. Jpn J Cancer Clin 26:1239–1243.Google Scholar
  15. 15.
    Kodama Y, Inokuchi K, Soejima K et al., 1983. Growth patterns and prognosis in early gastric carcinoma. Cancer 51:320–326.PubMedCrossRefGoogle Scholar
  16. 16.
    Inokuchi K. et al., 1983. Differentiation of growth patterns of early gastric carcinoma determined by cytophotometric DNA analysis. Cancer 51:1138–1141.PubMedCrossRefGoogle Scholar
  17. 17.
    Nagata T, Ikeda M, Nakayama F, 1983. Changing state of gastric cancer in Japan. Histologic perspective of the past 76 years. Am J Surg 145:226–233.PubMedCrossRefGoogle Scholar
  18. 18.
    Ostertag H, Georgii A, 1979. Early gastric cancer: A morphological study of 144 cases. Path Res Pract 164:294–315.PubMedCrossRefGoogle Scholar
  19. 19.
    Evans O, Graven JL, Murphy F, Cleary BK, 1978. Comparison of ‘early gastric cancer’ in Britain and Japan. Gut 19:1–19.PubMedCrossRefGoogle Scholar
  20. 20.
    Stiel D, Barrat PJ, 1982. Early gastric cancer. Med J Aust 2:369–371.PubMedGoogle Scholar
  21. 21.
    Green P, O’Toole K, Weinberg L, Goldfarb J, 1981. Early gastric cancer. Gastroenterology 81:247–256.PubMedGoogle Scholar
  22. 22.
    Bogomoletz WV, 1984. Early gastric cancer. Am J Surg Pathol 8:381–391.PubMedCrossRefGoogle Scholar
  23. 23.
    Oleagoitia JM, Echevarria A, Santidrian JI, et al., 1986. Early gastric cancer. Br J Surg 73:804–806.PubMedCrossRefGoogle Scholar
  24. 24.
    Mori M, Sugimachi K, Ohiwa T, et al., 1985. Early gastric carcinoma in Japanese patients under 30 years of age. Br J Surg 72:289–291.PubMedCrossRefGoogle Scholar
  25. 25.
    Collins WT, Gail EA, 1952. Gastric carcinoma: A multicentric lesion. Cancer 5:52–62.CrossRefGoogle Scholar
  26. 26.
    Moertel CG, Bargain JA, Soule EH, 1957. Multiple gastric cancers: Review of the literature and study of 42 cases. Gastroenterology 32:1095–1103.PubMedGoogle Scholar
  27. 27.
    Kubo A, Fujii A, Nishi M, 1968. Multiple primary cancer of the stomach with special reference to gastric cancer in its early stage. I to Cho 3:1497–1506.Google Scholar
  28. 28.
    Moertel CG, 1973. In Cancer Medicine (Holland JM, Frei E III, eds). Philadelphia: Lee & Febiger, pp. 1527–1541.Google Scholar
  29. 29.
    Noguchi Y, Ohta H, Tagaki K, et al., 1985. Synchronous multiple early gastric carcinoma: A study of 178 cases. World J Surg 11:127–139.Google Scholar
  30. 30.
    Furakawa H, Iwanaga T, Ichikawa T, et al., 1985. Multiple gastric cancers. Jpn J Gastroenterol Surg 18:651–654.Google Scholar
  31. 31.
    Mitsudomi T, Watanabe A, Matsuska T, et al., 1989. A clinicopathological study of synchronous multiple gastric cancer. Br J Surg 76:237–240.PubMedCrossRefGoogle Scholar
  32. 32.
    Lawrence WT, Lawrence W Jr., 1980. Gastric cancer: The surgeon’s viewpoint. Semin Oncol 7:400–417.PubMedGoogle Scholar
  33. 33.
    Gunderson LL, Sosin H, 1982. Adenocarcinoma of the stomach: Areas of failure in a reoperation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8:1–11.PubMedCrossRefGoogle Scholar
  34. 34.
    Clark CG, Fresini A, Gledhill T, 1985. Cancer following gastric surgery. Br J Surg 72:591–594.PubMedCrossRefGoogle Scholar
  35. 35.
    Milton-Thompson GJ, Lightfoot NF, Ahmet Z, et al., 1982. Intragastric acidity, bacteria, nitrite and N-nitroso compounds before, during and after cimetidine treatment. Lancet 1:1091–1095.PubMedCrossRefGoogle Scholar
  36. 36.
    Gledhill T, Leicester RJ, Addis B, et al., 1984. Epidermic hypochlorhydria. Br Med J 290:1383–1386.CrossRefGoogle Scholar
  37. 37.
    Drasar BS, Hill MJ, 1974. Role of bacteria in the aetiology of cancer. In Human Intestinal Microflora. London: Academic Press, p. 193.Google Scholar
  38. 38.
    Oshima H, Bartbsh H, 1981. Quantitative estimation of endogenous nitrosation in humans by monitoring N-nitroproline secreted in the urine. Cancer Res 41:3658–3662.Google Scholar
  39. 39.
    Jass JR, Filipe MI, 1979. A variant of intestinal metaplasia associated with gastric carcinoma: A histochemical study. Histopathology 3:191–199.PubMedCrossRefGoogle Scholar
  40. 40.
    Jass JR, Filipe MI, 1980. Sulphomucins and precancerous lesions of the human stomach. Histopathology 4:271–279.PubMedCrossRefGoogle Scholar
  41. 41.
    Filipe MI, Potet F, Bogomletz WV, et al., 1985. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut 26:1319–1326.PubMedCrossRefGoogle Scholar
  42. 42.
    Balfour DC, 1922. Factors influencing the life expectancy of patients operated on for gastric ulcer. Ann Surg 76:405–408.PubMedCrossRefGoogle Scholar
  43. 43.
    Peitsch W, Becker HD, 1979. Was istgesischent in der pathogenese and haufigkeit des primaren karzinomas in operierten. Magen Chirurg 50:33–48.Google Scholar
  44. 44.
    Mortensen NJMcC, Thomas WEG, Jones SM, 1984. Endoscopic screening for pre-malignant changes 25 years after gastrectomy: Results of a five-year prospective study. Br J Surg 71:363–367.PubMedCrossRefGoogle Scholar
  45. 45.
    Fischer AB, Graem N, Jensen OM, 1983. Risk of gastric cancer after Billroth II resection for duodenal ulcer. Br J Surg 70:552–554.PubMedCrossRefGoogle Scholar
  46. 46.
    Bowden LA, 1967. Surgery of locally recurrent gastric cancer. In Neoplasms of the Stomach (McNeer G, Pack GT, eds). Philadelphia: J.B. Lippincott, pp. 332–340.Google Scholar
  47. 47.
    Miwa K, 1979. Cancer of the stomach in Japan. Gann Monogr Cancer Res 22:61–65.Google Scholar
  48. 48.
    Pichlmayer R, Meyer HJ, 1981. Patterns of recurrence in relation to therapeutic strategy. In Gastric Cancer (Fielding JWL, ed). Oxford: Pergammon, pp. 171–190.Google Scholar
  49. 49.
    Douglass HO Jr., Nava MR, 1985. Gastric adenocarcinoma: Management of the primary disease. Semin Oncol 12:32–45.PubMedGoogle Scholar
  50. 50.
    Sugarbaker PH, Cunliffe WJ, Belliveau JF, et al., 1988. Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treat 1:66–79.Google Scholar
  51. 51.
    Weiss L, 1985. Metastatic inefficiency. In Principles of Metastasis (Weiss L, ed). New York: Academic Press, pp. 134–159.Google Scholar
  52. 52.
    Stanley JR, Beckwith JB, Fuller RP, Katz SI, 1982. A specific antigenic defect of the basement membrane is found in basal cell carcinoma but not in other epidermal tumours. Cancer 50:1486–1490.PubMedCrossRefGoogle Scholar
  53. 53.
    Lohe KJ, 1978. Early squamous cell carcinoma of the uterine cervix, III. Frequency of lymph node metastases.Gynecol Oncol 6:51–59.Google Scholar
  54. 54.
    Liotta LA, Kleinerman J, Saidel GM, 1976. The significance of haematogenous tumour cell clumps in the metastatic process. Cancer Res 36:889–894.PubMedGoogle Scholar
  55. 55.
    Rippe B, Stelin G, 1987. Peritoneal transport of water and solutes. In Peritoneum and Peritoneal Access (Tranberg K-G, ed). Abstracts of the First International Meeting, Lund, Sweden, p. 41.Google Scholar
  56. 56.
    Dedrick RL, Myers CE, Bungay PM, et al., 1978. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–11.PubMedGoogle Scholar
  57. 57.
    Ozols RF, Young RC, Speyer JL, et al., 1982. Phase I and pharmacologic studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42:4265–4269.PubMedGoogle Scholar
  58. 58.
    Dunnington, Trainer, Greig, Poste (unpublished work), 1986. Cited in EIGreig RG, Schein PS, 1900. Therapy of gastrointestinal cancer. Scand J Gastroenterol 117:9–25.Google Scholar
  59. 59.
    Myers CE, Collins JM, 1983. Pharmacology of intraperitoneal chemotherapy. Cancer Invest 1:395–407.PubMedCrossRefGoogle Scholar
  60. 60.
    Colcher D, Carrasquillo JA, Sugarbaker PH, et al., 1987. Complementation of intra cavitary and intravenous administration of anti-tumor antibody. Cancer Res 47:1185–1189.PubMedGoogle Scholar
  61. 61.
    Rogers KG, Carr BI, Tokes ZA, 1983. Cell surface-mediated cytotoxicity of polymer bound adriamycin against drug resistant hepatocytes. Cancer Res 43:2741–2272.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • W. J. Cunliffe

There are no affiliations available

Personalised recommendations